Changes in plasma d-serine, l-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment

• Published in: Neuroscience letters 2014-10, Vol.582, p.93-98
• Main Authors: Yamamori, Hidenaga, Hashimoto, Ryota, Fujita, Yuko, Numata, Shusuke, Yasuda, Yuka, Fujimoto, Michiko, Ohi, Kazutaka, Umeda-Yano, Satomi, Ito, Akira, Ohmori, Tetsuro, Hashimoto, Kenji, Takeda, Masatoshi
• Format: Article
• Language: English
• Subjects: Adult; Antipsychotic Agents - therapeutic use; Case-Control Studies; Clozapine; Clozapine - therapeutic use; Female; Glutamic Acid - blood; Glutamine - blood; Glycine; Glycine - blood; Humans; Male; Middle Aged; Plasma; Schizophrenia - blood; Schizophrenia - drug therapy; Serine; Serine - blood; Serine - chemistry; Stereoisomerism; Treatment Failure; Treatment-resistant schizophrenia
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/j.neulet.2014.08.052

•The plasma d-/l-serine ratio was lower in schizophrenia before clozapine treatment.•The plasma d-/l-serine ratio increased in response to clozapine treatment.•The plasma glycine/l-serine ratio increased in response to clozapine treatment.•The glycine/l-serine ratio was higher in schizophrenia after clozapine treatment. Hypofunction of the N-methyl-d-aspartate (NMDA) subtype of glutamate receptors may be involved in the pathophysiology of schizophrenia. Many studies have investigated peripheral NMDA receptor-related glutamatergic amino acid levels because of their potential as biological markers. Peripheral d-serine levels and the ratio of d-serine to total serine have been reported to be significantly lower in patients with schizophrenia than in controls. Peripheral d-serine levels and the d-/l-serine ratio have also been reported to significantly increase in patients with schizophrenia as their clinical symptoms improve from the time of admission to the time of discharge. In this study, we examined whether peripheral NMDA receptor-related glutamatergic amino acids levels were altered in patients with treatment-resistant schizophrenia compared to controls and whether these peripheral amino acids levels were altered by clozapine treatment. Twenty-two patients with treatment-resistant schizophrenia and 22 age- and gender-matched healthy controls were enrolled. The plasma levels of d-serine, l-serine, glycine, glutamate, and glutamine were measured before and after clozapine treatment. We found that the plasma levels of d-serine and the d-/l-serine ratio were significantly lower in the patients before clozapine treatment than in the controls. The d-/l-serine ratio was significantly increased by clozapine treatment in patients, and no significant difference was observed in the plasma levels of d-serine and the d-/l-serine ratio between the patients after clozapine treatment and the controls. We also found that plasma glycine levels and the glycine/l-serine ratio were significantly increased following clozapine treatment in the patients, and the glycine/l-serine ratio was significantly higher in the patients after clozapine treatment than in the controls. There was no significant difference in the plasma levels of glutamate and glutamine both between the controls and patients and between before and after clozapine treatment. This study firstly demonstrated changes of d-/l-serine and glycine/l-serine ratio between before and after clozapine treatment, suggestin